Annual accounts receivable:
$113.30M+$7.75M(+7.34%)Summary
- As of today (June 24, 2025), PCRX annual accounts receivable is $113.30 million, with the most recent change of +$7.75 million (+7.34%) on December 31, 2024.
- During the last 3 years, PCRX annual accounts receivable has risen by +$16.99 million (+17.64%).
- PCRX annual accounts receivable is now at all-time high.
Performance
PCRX Accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly accounts receivable:
$104.75M-$8.56M(-7.55%)Summary
- As of today (June 24, 2025), PCRX quarterly accounts receivable is $104.75 million, with the most recent change of -$8.56 million (-7.55%) on March 31, 2025.
- Over the past year, PCRX quarterly accounts receivable has increased by +$3.11 million (+3.06%).
- PCRX quarterly accounts receivable is now -7.55% below its all-time high of $113.30 million, reached on December 31, 2024.
Performance
PCRX Quarterly accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Accounts receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
PCRX Accounts receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +7.3% | +3.1% |
| 3 y3 years | +17.6% | +13.7% |
| 5 y5 years | +138.4% | +168.7% |
PCRX Accounts receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +17.6% | -7.5% | +15.0% |
| 5 y | 5-year | at high | +138.4% | -7.5% | +168.7% |
| alltime | all time | at high | +9413.4% | -7.5% | >+9999.0% |
PCRX Accounts receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $104.75M(-7.6%) |
| Dec 2024 | $113.30M(+7.3%) | $113.30M(+12.6%) |
| Sep 2024 | - | $100.65M(-3.9%) |
| Jun 2024 | - | $104.78M(+3.1%) |
| Mar 2024 | - | $101.64M(-3.7%) |
| Dec 2023 | $105.56M(+7.3%) | $105.56M(+8.9%) |
| Sep 2023 | - | $96.96M(-2.1%) |
| Jun 2023 | - | $99.08M(+6.3%) |
| Mar 2023 | - | $93.20M(-5.3%) |
| Dec 2022 | $98.40M(+2.2%) | $98.40M(+5.3%) |
| Sep 2022 | - | $93.47M(+2.6%) |
| Jun 2022 | - | $91.11M(-1.1%) |
| Mar 2022 | - | $92.10M(-4.4%) |
| Dec 2021 | $96.32M(+81.6%) | $96.32M(+92.7%) |
| Sep 2021 | - | $49.98M(-26.9%) |
| Jun 2021 | - | $68.36M(+30.0%) |
| Mar 2021 | - | $52.58M(-0.9%) |
| Dec 2020 | $53.05M(+11.6%) | $53.05M(+15.0%) |
| Sep 2020 | - | $46.14M(+4.8%) |
| Jun 2020 | - | $44.01M(+12.9%) |
| Mar 2020 | - | $38.99M(-18.0%) |
| Dec 2019 | $47.53M(+25.1%) | $47.53M(+11.6%) |
| Sep 2019 | - | $42.57M(+3.5%) |
| Jun 2019 | - | $41.15M(+3.5%) |
| Mar 2019 | - | $39.77M(+4.6%) |
| Dec 2018 | $38.00M(+20.0%) | $38.00M(+10.9%) |
| Sep 2018 | - | $34.27M(-3.9%) |
| Jun 2018 | - | $35.64M(+14.2%) |
| Mar 2018 | - | $31.20M(-1.4%) |
| Dec 2017 | $31.66M | $31.66M(+17.2%) |
| Sep 2017 | - | $27.02M(-1.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2017 | - | $27.47M(-0.8%) |
| Mar 2017 | - | $27.70M(-7.5%) |
| Dec 2016 | $29.94M(+15.8%) | $29.94M(+11.9%) |
| Sep 2016 | - | $26.77M(-6.6%) |
| Jun 2016 | - | $28.65M(+10.6%) |
| Mar 2016 | - | $25.90M(+0.2%) |
| Dec 2015 | $25.86M(+15.6%) | $25.86M(-0.2%) |
| Sep 2015 | - | $25.92M(+6.7%) |
| Jun 2015 | - | $24.28M(-0.9%) |
| Mar 2015 | - | $24.51M(+9.6%) |
| Dec 2014 | $22.37M(+53.3%) | $22.37M(+9.0%) |
| Sep 2014 | - | $20.52M(-0.1%) |
| Jun 2014 | - | $20.55M(+28.7%) |
| Mar 2014 | - | $15.97M(+9.5%) |
| Dec 2013 | $14.59M(+235.2%) | $14.59M(+49.3%) |
| Sep 2013 | - | $9.77M(+26.0%) |
| Jun 2013 | - | $7.76M(+47.9%) |
| Mar 2013 | - | $5.24M(+20.5%) |
| Dec 2012 | $4.35M(+106.0%) | $4.35M(+77.0%) |
| Sep 2012 | - | $2.46M(-23.5%) |
| Jun 2012 | - | $3.21M(+273.7%) |
| Mar 2012 | - | $860.00K(-59.3%) |
| Dec 2011 | $2.11M(+77.4%) | $2.11M(+41.2%) |
| Sep 2011 | - | $1.50M(+41.8%) |
| Jun 2011 | - | $1.05M(-41.7%) |
| Mar 2011 | - | $1.81M(+52.0%) |
| Dec 2010 | $1.19M(-18.1%) | $1.19M(-52.9%) |
| Sep 2010 | - | $2.53M(-22.2%) |
| Jun 2010 | - | $3.25M(+123.7%) |
| Dec 2009 | $1.46M(-43.7%) | $1.46M |
| Dec 2008 | $2.58M | - |
FAQ
- What is Pacira BioSciences annual accounts receivable?
- What is the all time high annual accounts receivable for Pacira BioSciences?
- What is Pacira BioSciences annual accounts receivable year-on-year change?
- What is Pacira BioSciences quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Pacira BioSciences?
- What is Pacira BioSciences quarterly accounts receivable year-on-year change?
What is Pacira BioSciences annual accounts receivable?
The current annual accounts receivable of PCRX is $113.30M
What is the all time high annual accounts receivable for Pacira BioSciences?
Pacira BioSciences all-time high annual accounts receivable is $113.30M
What is Pacira BioSciences annual accounts receivable year-on-year change?
Over the past year, PCRX annual accounts receivable has changed by +$7.75M (+7.34%)
What is Pacira BioSciences quarterly accounts receivable?
The current quarterly accounts receivable of PCRX is $104.75M
What is the all time high quarterly accounts receivable for Pacira BioSciences?
Pacira BioSciences all-time high quarterly accounts receivable is $113.30M
What is Pacira BioSciences quarterly accounts receivable year-on-year change?
Over the past year, PCRX quarterly accounts receivable has changed by +$3.11M (+3.06%)